Analyst Ratings February 9, 2026

Mizuho Inches Up Aflac Price Target to $107 While Retaining Underperform Call

Analyst adjusts valuation on Japan benefit ratio and buyback support amid investment income and currency headwinds

By Jordan Park AFL
Mizuho Inches Up Aflac Price Target to $107 While Retaining Underperform Call
AFL

Mizuho has raised its price target for Aflac Inc. to $107.00 from $104.00 but kept an Underperform rating, leaving the target below the insurer's prevailing share price of $113.20. The firm attributed the modest upward revision to a lower benefit ratio in Japan and heavier share repurchases, which lifted its 2026 earnings per share projection by 1% to $7.35. Offsetting factors include weaker net investment income from lower floating rates and a currency drag as the Japanese yen depreciates versus the U.S. dollar. Aflac's market value stands at $58.7 billion and the company yields 2.08%, while its fourth-quarter 2025 results showed an EPS shortfall but revenue strength.

Key Points

  • Mizuho raised its Aflac price target to $107 from $104 but retained an Underperform rating; the target is below the current trading price of $113.20.
  • A lower benefit ratio in Japan and increased share buybacks led Mizuho to raise its 2026 EPS estimate by 1% to $7.35; InvestingPro data confirms active repurchases supporting a 13% return on equity.
  • Headwinds include reduced net investment income from lower floating rates and a currency drag as the Japanese yen weakens; the firm cut its 2027 EPS estimate by 1% to $7.75, with both years' estimates aligned with consensus.

Mizuho has revised its price target on Aflac Inc. (NYSE: AFL) upward to $107.00 from $104.00 while maintaining an Underperform rating on the insurance company's stock. The new target remains below Aflac's most recently reported trading price of $113.20, a gap Mizuho says implies an expected negative return for shareholders over the coming period.

Valuation and return outlook

The 3% increase in the price target primarily reflects a valuation roll-forward, according to Mizuho. Even with the higher target, the firm projects a negative 6% return for Aflac's shares. That outlook is noteworthy given the stock's solid performance over the past year, which has produced a 15.6% price gain.

Drivers behind the revision

  • Lower benefit ratio in Japan: Mizuho cites a reduction in the benefit ratio in Aflac's Japanese operations as a favorable development that supports the higher target.
  • Share repurchases: Increased buybacks by management also contributed to the change. Mizuho's modeling incorporated greater repurchases, and InvestingPro data corroborates that management has been aggressive in repurchasing shares, a factor that supports the company's reported 13% return on equity.

These positives helped push Mizuho's 2026 earnings per share estimate up by 1% to $7.35.

Offsets and headwinds

Partially offsetting those favorable items, Mizuho noted two material headwinds:

  • Net investment income pressure: Lower floating interest rates have diminished net investment income, weighing on the insurer's profitability.
  • Currency effects: A weakening Japanese yen versus the U.S. dollar has increased the currency drag on results.

The firm trimmed its 2027 EPS estimate by 1% to $7.75. Mizuho also indicated that its 2026 and 2027 estimates remain consistent with consensus forecasts.

Capital return and income appeal

Aflac's market capitalization is reported at $58.7 billion. The company offers a dividend yield of 2.08%, a level that may be of interest to income-oriented investors even as earnings and investment-income dynamics create uncertainty.

Recent quarterly results

In its fourth-quarter 2025 report, Aflac posted diluted earnings per share of $1.57, below the consensus expectation of $1.70, a miss equivalent to a 7.65% downside surprise. Revenue for the quarter, however, came in at $4.87 billion, ahead of the $4.28 billion forecast, representing a 13.79% upside surprise. Market commentary following the release has noted the tension between the EPS shortfall and stronger-than-expected sales, and analysts had not enacted upgrades or downgrades in the immediate aftermath of the report.

Investor takeaways

Mizuho's adjustment leaves the stock trading above the firm's target and portrays a mixed picture: operational and capital-return improvements on one hand, and investment-income and currency pressures on the other. Investors and market participants will likely monitor subsequent quarterly updates and any changes to buyback or capital-return programs for clearer signals on near-term earnings trajectories.

Risks

  • Weaker net investment income tied to lower floating interest rates could compress insurer profitability, impacting the financials and insurance sector.
  • Continued depreciation of the Japanese yen versus the U.S. dollar would increase currency-related headwinds for Aflac's Japan-centric operations, affecting multinational insurers and foreign-exchange-sensitive sectors.
  • The company's recent EPS miss, despite revenue outperformance, introduces execution risk and could influence analyst sentiment and investor positioning in financial and insurance equities.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026